These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32274544)

  • 1. [Combination therapy for metastatic hormone-sensitive prostate cancer: What? When? For whom?].
    Thomas C; Ohlmann CH
    Urologe A; 2020 Jun; 59(6):665-672. PubMed ID: 32274544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S; Lang JM; Jarrard DF
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Apalutamide, Erleada®].
    Sautois B; Denis C
    Rev Med Liege; 2022 Oct; 77(10):609-615. PubMed ID: 36226398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of metastatic, castration-resistant prostate cancer].
    von Amsberg G; Merseburger AS
    Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
    Joseph N; Anjanappa M; Choudhury A
    Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic.
    Rahnama'i MS
    Am J Mens Health; 2022; 16(4):15579883221115593. PubMed ID: 35950609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C; Bögemann M; Goebell PJ; Hammerer P; Machtens S; Pfister D; Schwentner C; Steuber T; von Amsberg G; Schostak M
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
    Grisay G; Lavaud P; Fizazi K
    Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
    Buonerba C; Ferro M; Dolce P; Crocetto F; Verde A; Lucarelli G; Scafuri L; Facchini S; Vaia A; Marinelli A; Terracciano D; Montella L; Longo N; Imbimbo C; Mirone V; Di Lorenzo G; De Placido S; Sonpavde G
    Crit Rev Oncol Hematol; 2020 Jul; 151():102992. PubMed ID: 32474391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Modern treatment of metastatic hormone-sensitive prostate cancer].
    Küronya Z; Bíró K; Géczi L; Maráz A
    Orv Hetil; 2018 Oct; 159(41):1664-1671. PubMed ID: 30295043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of antiandrogen therapy for treating prostate cancer.
    Ricci F; Buzzatti G; Rubagotti A; Boccardo F
    Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of metastatic hormone-naive prostate cancer at diagnosis].
    Colassin A; Denis C; Hermesse J; Waltregny D; Sautois B
    Rev Med Liege; 2021 May; 76(5-6):496-501. PubMed ID: 34080386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
    Sun G; Chen X; Gong U; Chen Y; Li G; Wei F; Jiang A; Niu Y; Shang Z
    Future Oncol; 2019 Apr; 15(10):1167-1179. PubMed ID: 30741558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.
    Shiota M; Eto M
    Int J Urol; 2016 May; 23(5):360-9. PubMed ID: 27062039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer.
    Saad F; Fizazi K
    Urology; 2015 Nov; 86(5):852-61. PubMed ID: 26282624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
    Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
    Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.